Avid Bioservices Inc (CDMO)

[entdoc]

wildhorses, nice post. Mostly in agreement. Management has said, "we have it". They have not stepped a foot wrong in that regard. If this subset can be identified early on in the treatment cycle, long before end-stage disease, we have a winner, depending on what percentage of responders we are talking about. If we have a biomarker for 1% of the population of diseased subjects vs., say, 30%, then we are in business. Lung cancer involves an enormous demographic worldwide. You think it's bad here. Think China. makes me wonder about 2C3 in Russia.